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Purpose: To evaluate the safety and efﬁcacy of combined lipid-modifying agents (statin
+ fenoﬁbrate) on plasma lipid proﬁle including the atherogenic index of plasma (AIP = log
[TG/HDL-C]) in patients at high and very high cardiovascular (CV) risk and mixed dyslipi-
demia.
Method: A total of 81 patients (53 males, 28 females; 60  9.8 years) were included. Mixed
dyslipidemia was deﬁned as having 2 of the following 3 lipid abnormalities: LDL-cholesterol
(C) >2.5 mmol/l, HDL-C <1.0 mmol/l in males and <1.3 mmol/l in females, triglycerides (TG)
>1.7 mmol/l. Global CV risk was estimated according to the current European guidelines.
Management with fenoﬁbrate (160–267 mg) + atorvastatin (10–20 mg) or simvastatin (20–
40 mg) was indicated for 6 months. Males and females were stratiﬁed according to the AIP
risk categories: AIP <0.11 (low risk), AIP >0.21 (high risk).
Results: About 3/4 of high or very high CV risk patients with mixed dyslipidemia (n = 81)
suffer from impaired glucose metabolism (44% had type 2 diabetes, 30% had impaired fasting
glucose). Six-months combined therapy reduced LDL-C (by 29%) and TG (by 40%) signiﬁ-
cantly, but the increase of HDL-C (by 3%) was not signiﬁcant. There were 47% of males and
57% of females who achieved the target LDL-C levels (<25 or <1.8 mmol/l) and 14% of males
and 37% of females who received non-HDL-C <2.6 mmol/l at the end of the study. Also AIP
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was decreased signiﬁcantly in majority of the patients (high risk AIP decreased from 87% to
47% of males and from 71% to 25% of females).
Conclusion: The combined lipid-modifying therapy led to a signiﬁcant improvement of the
plasma lipid proﬁle, particularly of LDL-C, TG, non-HDL-C and AIP. Atherogenic index of
plasma seems to be a very useful marker of CV risk in high and very high CV risk patients
with mixed dyslipidemia and glucose abnormalities. More intensive management is needed
in those patients.
# 2014 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z  o.o.
All rights reserved.
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.Introduction
Patients with established atherosclerotic vascular diseases
(e.g. myocardial infarction, stroke, chronic coronary heart
disease, peripheral artery occlusive disease etc.) or subjects
with documented cardiovascular disease (CVD) by invasive or
non-invasive testing, patients with diabetes mellitus (DM) and
one or more CV risk factors and/or target organ damage,
patients with severe chronic kidney disease or subjects in
primary prevention of CVD having an absolute risk of fatal CV
events 10% according to the SCORE risk chart are considered
as patients at very high CV risk. Patients with DM without any
CV risk factors or target organ damage, patients with moderate
chronic kidney disease, markedly elevated risk factors or
global CV risk 5% and <10% in primary CVD prevention are
considered as patients at high CV risk. All these very high or
high-risk patients need to be motivated to modify their
lifestyle (primarily to quit smoking, to have a healthy diet,
exercise regularly and reduce stress) as well as initiate
pharmacological therapy of conventional risk factors. Target
values of blood pressure below 140/90 or around 130/80 mm Hg
(with individual approach) and LDL-cholesterol (C) <2.5 mmol/
l for patients at high CV risk and LDL-C <1.8 mmol/l or
reduction of LDL-C 50% in very high-risk patients. Obesity
and diabetes require intensive treatment [1]. According to the
European Guidelines for the management of dyslipidemias
(2011), which were accepted by the Czech Society of Athero-
sclerosis, the other lipid fractions should be tested in high-risk
or very high-risk patients [2]. Mixed dyslipidemia described by
elevated TG plus reduced HDL-C concentration is called
atherogenic dyslipidemia. This dyslipidemia associates with
insulin resistance and belongs to the cluster of the metabolic
syndrome and also to type 2 DM frequently. Atherogenic
dyslipidemia is considered as a main source of residual
vascular risk in patients, who have aimed the target values of
LDL-C due to statin therapy in most cases. Even though the
PROCAM study has proven that an elevated TG level increases
CVD risk independently of the level of LDL-C [3], the European
Guidelines do not mention either plasma TG or HDL-C as
primary treatment aims, even for those patients suffering
from dyslipidemia with a high CV risk. To achieve optimal
levels of fasting plasma TG <1.7 mmol/l and HDL-C
>1.3 mmol/l in women and >1.0 mmol/l in men can be
considered as secondary or optional aims especially in
patients with metabolic syndrome and/or type 2 DM [2]. Both
the National Cholesterol Education Program (NCEP) III and theEuropean Guidelines recommend to count and reduce non-
HDL-C to <3.3 mmol/l and apolipoprotein B (Apo-B) <0.9 g/l for
patients with elevated TG and moderate CV risk [4]. In patients
with type 2 diabetes and very high CV risk, who have achieved
recommended goal for LDL-C <1.8 mmol/l, to reduce non-HDL-
C <2.6 and Apo-B <0.8 g/l represent the secondary targets.
Some years ago, Dobiasova and Frohlich proposed an
atherogenic index of plasma (AIP = log[TG/HDL-C]) that takes
into account the importance of plasma concentrations of TG
and HDL-C, which is based on laboratory ﬁndings concerning
the mechanism of regulation of the size of lipoproteins in the
general population [5,6]. It demonstrates that a logarithmic
transformation of the molar concentrations of TG and HDL-C is
closely related to the sizes of HDL-C, LDL-C and VLDL-C
particles, which are now considered to be new-generation
indicators of CV risk and deﬁne the atherogenic genotype of
plasma more precisely than classical biochemical indicators
total cholesterol, LDL-C, HDL-C, TG, Apo-A, Apo-B, etc.
However, these tests are time-consuming and are expensive
and the result cannot be expressed as a single number, but AIP
can be used for monitoring of actual lipoprotein proﬁle and
predicting CV risk [7,8].
In this study, we focused on patients with mixed
dyslipidemia and high or very high CV risk, for whom we
treated with a combination of statin and fenoﬁbrate. The
objective of the study was to evaluate the safety and efﬁcacy of
this combined therapy on individual components of the lipid
spectrum, including AIP.
Method
The study took place some years ago in 6 lipid outpatient
clinics: at the 2nd Medical Department of the University
Hospital in Pilsen, Department of Clinical Biochemistry of the
St Anna University Hospital in Brno, the 3rd Medical Depart-
ment of the University Hospital in Prague, the Diabetology
Center of the Prague Institute for Clinical and Experimental
Medicine, the 2nd Medical Department of the St Anna
University Hospital in Brno, Department of Metabolic Care
and Gerontology of the University Hospital in Hradec Kralove.
Patients were recruited if they met 2 inclusion criteria: ﬁrstly,
patients at high or very high CV risk according to the current
guidelines mentioned above [2]. Secondly, patients with
untreated mixed dyslipidemia or treated with statin or ﬁbrate
monotherapy deﬁned as having 2 of the following 3 lipid
abnormalities: LDL-C >2.5 mmol/l, HDL-C <1.0 mmol/l in
Table 1 – Baseline characteristics of the sample (53 men
and 28 women) with mixed dyslipidemia and high
cardiovascular risk.
Factor Mean  SD Median (range)
Age (years) 59.6  9.8 60 (34–83)
BMI (kg/m2) 31.9  22.5 29 (22–39)
Waist (cm) 100  15 102 (64–116)
Systolic BP (mm Hg) 133  12 134 (75–162)
Diastolic BP (mm Hg) 83  8 81 (64–101)
Pulse (n/min) 70  8 70 (52–91)
Total C (mmol/l) 5.92  1.30 5.76 (3.40–12.25)
LDL-C (mmol/l) 3.45  0.95 3. 41 (1.70–6.77)
HDL-C (mmol/l) 1.16  0.27 1.14 (0.37–2.08)
Triglycerides (mmol/l) 3.61  2.16 2.93 (1.50–12.53)
Apolipoprotein A (g/l) 1.33  0.43 1.30 (0.89–2.37)
Apolipoprotein B (g/l) 1.13  0.33 1.13 (0.52–1.77)
Fasting glycemia (mmol/l) 6.41  1.50 5.95 (4.40–12.90)
HbA1C (mmol/mol) 51  8.2 49 (38–70)
ALT (mkat/l) 0.66  0.84 0.56 (0.20–1.47)
AST (mkat/l) 0.49  0.19 0.45 (0.21–1.82)
GMT (mkat/l) 0.78  0.66 0.57 (0.16–4.11)
Creatine kinase (mkat/l) 2.1  1.7 1.7 (0.6–13.2)
SD, standard deviation; BMI, body mass index; C, cholesterol;
HbA1C, glycosylated hemoglobin; ALT, alanineaminotransferase;
AST, aspartate aminotransferase; GMT, gamma glutamyltransfer-
ase.
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exclusion criteria of our study included current treatment with
combined lipid-lowering drugs, familiar hypercholesterolemia
treated with high doses of statins (atorvastatin >20 mg or
simvastatin >40 mg), an acute CV event during the last 3
months, BMI 40 kg/m2, the presence of fatal diseases, non-
adherence to treatment, serious psychiatric illnesses, ALT or
AST values >3-fold greater than the upper normal level,
creatine kinase (CK) >5-fold greater than the upper normal
level or myopathy in the patient history, creatinine levels
>150 mmol/l, glycosylated hemoglobin HbA1C >65 mmol/mol
(IFCC), disorder of the thyroid gland (hypo- or hyperthyreosis),
insulin-treated diabetes, women of working age with positive
pregnancy test. All patients gave written informed consent
before entering the study.
The study included 3 visits (I, II and III) to the hospital at
intervals of 3 months and 12 h fasting blood samples were
taken at each visit. At visit I, the start of the study, the patient
was reminded of the importance of a healthy lifestyle and
intervention was initiated for risk factors the patient had not
changed and health educational materials were given to the
patient. A combination therapy was administered to all
patients. Patients not already receiving a lipid-lowering drug
were given fenoﬁbrate (160 mg) + atorvastatin (10 mg) or
simvastatin (20 mg). For patients receiving any dose of ﬁbrate,
ﬁbrate was replaced by fenoﬁbrate (160 mg) + atorvastatin
(10 mg) or simvastatin (20 mg). For patients receiving statin in
any acceptable dosage, the dose was adjusted to atorvastatin
(10 mg) or simvastatin (20 mg) + fenoﬁbrate (160 mg). Patients
attended for visit II after 3 months of combination therapy and
a complete control lipidogram was made. If LDL-C <2.5 in high-
risk or <1.8 mmol/l in very high-risk patients were not
achieved, the dose of statin was increased (simvastatin to
40 mg or atorvastatin to 20 mg). For patients who did not
achieve the optimal values of TG <1.7 mmol/l or HDL-C
1.0 mmo/l in males or HDL-C 1.3 mmol/l in females, the
daily dose of fenoﬁbrate was increased to 267 mg. At visit III,
the participating physician decided whether the patient would
continue with the medication (if the patient achieved target
lipid values) or the therapy was adjusted as needed. The
patient was asked to recall all potentially adverse side effects
during the duration of the study and these were recorded.
We used the AIP (AIP = log[TG/HDL-C]) to evaluate the CV
risk for each patient [6]. AIP <0.11 was classiﬁed as low CV risk;
AIP 0.1–0.21 was classiﬁed as moderate CV risk; and AIP >0.21
was classiﬁed as high CV risk [7,8].
Total cholesterol (TC), TG, HDL-C and other biochemical
parameters were measured with an enzymatic autoanalyzer
(Beckman Coulter AU 680, Beckman Coulter Inc., USA). LDL-C
was calculated using the Friedewald formula and Apo-B and
Apo-AI were measured by an immunoturbidimetric assay.
These lipid parameters and the calculated values of non-HDL-
C and AIP were expressed according to the non-parametric
distribution as the medians and standard deviations of the
quartiles. Statistical analysis of the variation of individual lipid
parameters and AIP before the treatment started and 3 months
later (visit II versus visit I), at 3 months and at 6 months
following the initiation of the treatment (visit II versus visit III)
and before initiation of the treatment and 6 months later (visit
III versus visit I) was conducted using Friedman's test, whichcompares the values of medians. Decrease or increase in lipid
values and AIP were expressed in absolute values and in
percentages using the initial values as a base. The incidence of
adverse events was evaluated by analysis of variance
(ANOVA).
Results
The baseline data of 81 patients (53 males and 28 females)
included in the study are given in Table 1: 78% (74% males and
86% females) met the criterion of high LDL-C; 96% (98% males
and 96% females) met the criterion of high TG; and 49% (only
36% males and 75% females) of patients met the criterion of
low HDL-C. About 44% of patients suffer from type 2 DM, 27%
from atherosclerotic vascular disease (stable coronary heart
disease or ischemic stroke) and 29% patients were at high or
very high CV risk (5%). In more than half of non-diabetic
patients (53%) was assessed impaired fasting glucose during
the visit I, i.e. glucose level above 5.6 and below 7.0 mmol/l. It
means, that about 3/4 of all included patients at high or very
high CV risk had impaired glucose metabolism.
At visit II, the dose of statin was increased from 10 to 20 mg
of atorvastatin or from 20 to 40 mg of simvastatin for the 8
(10%) patients who had not achieved LDL-C <2.5 (<1.8) mmol/l;
the dose of fenoﬁbrate was increased to 267 mg for the 26 (32%)
patients who had not achieved TG <1.7 mmol/l or HDL-C was
not above the target value. The dose of both medications
needed to be increased in 32 (40%) patients and the doses of
one or both lipid-modifying drugs were increased in a total of
66 (82%) patients. The lipid parameters after 3 months and
after 6 months of combination therapy are given in Table 2. At
the end of the study the level of plasma LDL-C was decreased
Table 3 – Changes in AIP after 3 months and after 6 months of combination therapy.
Patients AIP median (quartile deviations) (Friedman test)
p
Visit I Visit II Visit III I–II II–III I–III
Men 0.459 (0.198; 1.184) 0.334 (0.193; 0.871) 0.251 (0.290; 0.856) 0.001 0.01 0.001
Women 0.332 (0.006; 1.490) 0.139 (0.511; 0.758) 0.049 (0.428; 0.725) 0.001 NS 0.001
Total 0.415 (0.006; 1.490) 0.248 (0.511; 0.871) 0.206 (0.428; 0.856) 0.001 0.01 0.001
AIP, atherogenic index of plasma [log(TG/HDL-C)]; visit I, baseline visit before treatment; visit II, after treatment for 3 months; visit III, after
treatment for 6 months (the end of the study).
Table 4 – Target LDL-C, HDL-C, TG,. AIP values, apo B and non-HDL-C in 53 men and 28 women before treatment and after 6
months of combination therapy.
Target lipid values Before treatment n (%) After treatment n (%)
Men Women Men Women
LDL-C < 2.5 (mmol/l) 8 (15) 4 (14) 25 (47) 16 (57)
HDL-C* (mmol/l) 34 (64) 7 (25) 44 (83) 11 (39)
TG < 1.7 (mmol/l) 1 (2) 1 (4) 22 (42) 18 (64)
#AIP < 0.10 0 (0) 3 (11) 18 (34) 16 (61)
##AIP > 0.21 46 (87) 20 (71) 25 (47) 7 (25)
Apo B < 0.8 (g/l) 2 (5) 4 (17) 13 (30) 11 (48)
Non-HDL-C < 2.6 (mmol/l) 1 (2) 0 7 (14) 10 (37)
LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglycerides; AIP, atherogenic index of plasma [log
(TG/HDL-C)]. Apo B, apolipopotein B; Non-HDL-C = total C minus HDL-C.
* HDL-C men > 1.0 mmol/l, women > 1.3 mmol/l.
# AIP < 0.10 low risk.
## AIP > 0.21 high risk.
Table 2 – Changes in plasma LDL-C, HDL-C, triglycerides, apolipoprotein B and non-HDL-C (medians).
Visit p (Friedman test)
I II III I–II II–III I–III
LDL-C (mmol/l) 3.41 2.79 2.53 *** ***
HDL-C (mmol/l) 1.14 1.14 1.16
Triglycerides (mmol/l) 2.93 2.10 1.78 *** *** ***
Apolipoprotein B (g/l) 1.13 0.96 0.83 *** ***
Non-HDL-C (mmol/l) 4.63 3.75 3.46 *** ***
LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; Visit I, baseline visit before treatment; visit II, after
treatment for 3 months; visit III, after treatment for 6 months (the end of the study).
*** p < 0.001.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 3 3 – e 1 3 9e136signiﬁcantly ( p < 0.001) by 29% and HDL-C was increased by
only 3% (not signiﬁcant), TG was decreased signiﬁcantly
( p < 0.001) by 40%, the level of Apo-B was decreased
signiﬁcantly ( p < 0.001) by 27%, and non HDL-C was decreased
signiﬁcantly ( p < 0.001) by 25%.
During the entire course of the therapy, AIP was decreased
signiﬁcantly ( p < 0.001) in the majority of patients receiving
combination therapy (Table 3). The mean value was decreased
by approximately half in males and to a greater extent in
females; AIP was unchanged in 8 (15%) males and in 2 (7%)
females. The proportion of patients at low risk AIP increased
from zero to 34% of males and from 11% to 61% of females
during the course of the treatment; conversely the number of
patients at high risk AIP decreased from 87% to 47% of males
and from 71% to 25% of females.Table 4 gives the numbers of males and females with target
lipid values and in the low risk AIP category before treatment
and those who achieved target lipid values and the low risk AIP
category after 6 months of combination therapy with statin
and ﬁbrate. At the end of the study, the target level of LDL-C
<2.5 mmol/l [1,8] was achieved by 47% of males and 57% of
females. HDL-C >1.0 mmol/l was achieved by 83% of males and
>1.3 mmol/l by 39% of females. Plasma TG <1.7 mmol/l was
achieved by 42% of males and by 64% of females. The target
value of non-HDL-C <2.6 mmol/l and apo-B <0.8 g/l was
achieved by 14% and 30% of males respectively and by 37%
and 48% of females respectively.
The few adverse effects associated with statin + fenoﬁbrate
therapy are given in Table 5. One patient entered the study
with a slightly elevated level of creatinine kinase
Table 5 – Adverse effects of combination therapy.
Visit I Visit II Visit III p
Muscle weakness 0 2 2 NS
Muscle pain 0 2 3 NS
Hair loss 0 1 2 NS
Fatigue 0 3 1 NS
Overall weakness 0 3 0 NS
Nausea 0 1 1 NS
Visit I, baseline visit before treatment; visit II, after treatment for 3
months; visit III, after treatment for 6 months (the end of the
study); NS, not signiﬁcant.
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out the study.
Discussion
About 3/4 of high or very high CV risk patients with mixed
dyslipidemia (n = 81) suffer from impaired glucose metabo-
lism: 44% had type 2 DM and 30% had impaired fasting glucose.
The low dose of lipid-modifying agents had to be increased in
most patients (82% of the sample) after the 3 months therapy:
statins in 10% of patients, ﬁbrates in 32% of patients and both
drugs in 40% of patients. It was found, that administration of
combined therapy with statin + fenoﬁbrate for 6 months
signiﬁcantly reduced levels of LDL-C (by 29%) and TG (by
40%), but the increase in the level of HDL-C (by 3%) was not
signiﬁcant. There were 47% of males and 57% of females who
achieved the recommended LDL-C levels (<2.5 or <1.8 mmol/l)
and 14% of males and 37% of females who received non-HDL-C
<2.6 mmol/l at the end of the study. Also AIP was decreased
signiﬁcantly in the majority of patients following combined
lipid-modifying therapy during the course of the study. Low
risk AIP was achieved in 34% of males and in 61% of females.
That was why the lipid-modifying therapy had to be intensi-
ﬁed in the majority of patients at the end of the study.
Even though 82% of patients were given increased doses of
lipid-modifying agents, the tolerance of combined treatment
was excellent. There was no occurrence of a serious adverse
event; i.e. there was no rhabdomyolysis, but muscle pain and
weakness were temporary and not associated with an increase
of enzymes speciﬁc to myopathy. It is in agreement with the
previous large lipid-modifying trials FIELD (The Fenoﬁbrate
Intervention and Event Lowering in Diabetes) and ACCORD
(The Action to Control Cardiovascular Risk in Diabetes), both of
them have conﬁrmed, that treatment of thousands of diabetic
patients with a combination of simvastatin and fenoﬁbrate
was very well tolerated and safe [9,10].
Furthermore, the effectiveness and tolerability of simva-
statin plus fenoﬁbrate for combined hyperlipidemia (SAFARI)
trial proved the same effects [11]. In that study, which
randomized 619 patients on simvastatin monotherapy
(20 mg) or simvastatin (20 mg) + fenoﬁbrate (160 mg) combi-
nation therapy, there was no incidence of rhabdomyolysis or
clinical myopathy. Nevertheless, after 12 months of treatment
combination therapy was more effective in reducing TG (24%
reduction) and LDL-C (6% additional reduction) and increasing
HDL-C (by an additional 9%) than statin monotherapy. Theresults of our study concur with many ﬁndings of the SAFARI
trial in the decrease of LDL-C and TG levels. Only the increase
in HDL-C was greater in the SAFARI study (mean 19% increase)
than in our study (mean 3% increase). This can be explained by
the fact that the patients in our trial had higher HDL-C levels at
baseline (mean 1.18 mmol/l) than those in the SAFARI trial
(mean 1.13 mmol/l), thus the effect of combined therapy was
less pronounced. It is known from the SAFARI study that
combination therapy increased the size of individual LDL
particles, which formed less dense and less atherogenic
particles. We expect that this change in LDL particle size
occurred in our study because of the reduction in plasma TG
levels and decrease of AIP.
Atherogenic index of plasma (AIP = log[TG/HDL-C]) reﬂects
not only the balance between risk and protective lipoproteins,
but also correlates with lipoprotein particle size and choles-
terol esteriﬁcation rate [12,13]. It seems to be very important
for the patients with mixed dyslipidemia, esp. in patients with
atherogenic dyslipidemia, in evaluation residual vascular risk
in patients with achieved LDL-C goal [14]. Reaven's group
published a study, in which they observed, that the TG/HDL-C
ratio is closely related to insulin resistance expressed as
increased levels of fasting insulin in a sample of overweight
individuals [15]. A TG/HDL-C ratio of 3 mg/dl was considered
borderline for the prediction of the presence of small dense
LDL particles in a Caucasian population. According to the
authors, this ratio could provide clinicians with a new marker
for hyperinsulinemia in patients of normal weight [16]. The
relationship between plasma insulin and fraction esteriﬁca-
tion rate (FERHDL) as well as between AIP and hyperinsulinemia
was reported by Dobiasova and Frohlich much earlier [1998],
than it was described by Reaven et al. [17].
There is not recommended any target level of TGs in the
European Guidelines, but TGs are an important regulator of
lipid metabolism and atherogenesis. An increased concentra-
tion of TGs is associated with a high concentration of
atherogenic HDL, LDL and VLDL particles and an increased
transport of cholesterol esters from HDL particles to lipopro-
tein containing Apo-B [12,18,19]. The ACCORD lipid trial
showed that treatment with ﬁbrates should be considered
as beneﬁcial for patients with type 2 DM treated by statins who
also have atherogenic dyslipidemia, deﬁned as TG 2.3 mmol/
l and HDL-C 0.9 mmol/l. Combined lipid-lowering therapy
(simvastatin + fenoﬁbrate) has signiﬁcantly reduced the prev-
alence of macrovascular complications (myocardial infarction,
stroke and cardiovascular mortality) [20]. Diabetics without
atherogenic dyslipidemia had no beneﬁt from the combined
lipid-lowering therapy with regard to the prevention of
macrovascular complications, but it reduced the progression
of microvascular complications [10].
In our study, the target levels of lipids were not achieved in
all patients despite an increase in the doses of statins and
fenoﬁbrate at visit II, after 3 subsequent months of combina-
tion therapy. The LDL-C target was not achieved by 53% of
males and 43% of females; that is why higher doses of statin
are needed for high and especially for very high risk patients
than the used. The TG optimal level was not reached by 58% of
males and 36% of females; and the HDL-C optimal level was
not reached by 17% of males and 61% of females; and 47% of
males and 25% of females remained at high-risk AIP. These
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frequently in women (HDL-C <1.3 mmol/l was found in 75% of
females and values of <1.0 mmol/l were found in 36% of
males). Combination therapy increased HDL-C levels to above
the target values in 19% of males and 14% of females.
Recommended target value of Apo-B <0.8 g/l and non-HDL-
C were achieved in 30% and 14% of males respectively and in
48% and 37% of females respectively. These results suggest
that very high risk patients need strong implementation of
non-pharmacological recommendations (low-fat diet, regular
physical activity, non-smoking) and also more intensive lipid-
lowering therapy, especially high dose of statins or more
effective statin (such as rosuvastatin) to achieve recom-
mended LDL-C values. To achieve the recommended values
of non-HDL-C and Apo-B in patients with high CV risk and
mixed dyslipidemia, higher dose of fenoﬁbrate and/or another
combination of lipid-modifying drugs would be useful; e.g.
statin + ezetimibe, ﬁbrate + ezetimibe or statin + ﬁbrate + eze-
timibe. The impact of combined lipid-modifying therapy
including ezetimibe on CVD morbidity and mortality need to
be proved, although smaller clinical studies have shown very
good effects not only on lipid metabolism but also on the other
risk factors in various patient groups [21,22]. Advised com-
bined therapy with nicotinic acid (niacin) is not possible in
Czech Republic, because the ﬁxed combination of niacin with
laropiprante (Tredaptiv) was removed from the drug register,
and separate niacin has not been registered anyway. New
lipid-modifying agents are on the way.
Conclusion
Combination therapy by statin and fenoﬁbrate in patients at
high or very high CV risk (majority of them had type 2 DM or
impaired fasting glucose) and mixed dyslipidemia [deﬁned as
the presence of 2 out of 3 pathological lipid parameter levels:
TG >1.7 mmol/l, LDL-C 2.5 [1,8] mmol/l, HDL-C <1.0 in males
and <1.3 mmol/l in females], was relatively effective and well
tolerated. It led to a signiﬁcant reduction in AIP (50% reduction
compared to baseline) as a surrogate of CV risk associated with
mixed dyslipidemia and insulin resistance. It is expected that a
combined lipid-modifying treatment could have a protective
effect regarding the incidence of CV disease and their
mortality, especially in patients at high and very high CV risk
and glucose metabolism abnormalities.
Not only primary goal, i.e. LDL-C targets (<2.5 or
<1.8 mmol/l), but also optimal values of TG (<1.7 mmol/l)
and HDL-C (>1.0 mmol/l in males and >1.3 mmol/l in females)
controlled by non-HDL-C (<2.6 mmol/l) or Apo-B levels (<0.8 g/l)
are recommended as a secondary goals of treatment in
patients with elevated TGs level according to the contemporary
guidelines. Atherogenic index of plasma used in our study
seems to be one of the important markers of atherogenic
risk in patients with mixed dyslipidemia, especially in patients
with atherogenic dyslipidemia (elevated TG and reduced
HDL-C), frequently occurring in type 2 diabetics or in patients
with insulin resistance or metabolic syndrome. The logarithmic
transformation of the molar concentrations of TG and HDL-C
is closely related to the size of HDL-C, LDL-C and VLDL-C
particles, which are considered to be new-generationindicators of CV risk and deﬁne the atherogenic genotype of
plasma more precisely than classical biochemical indicators.
More intensive therapy is needed in patients at high and very
high CV risk and mixed dyslipidemia; trends to the combination
of 2 or 3 lipid-modifying agents seem to be very useful in short
future.
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